T cell-based targeted immunotherapies for patients with multiple myeloma

• Verfasst von: Wang, Lei [VerfasserIn]
• Verfasst von: Jin, Nan [VerfasserIn]
• Verfasst von: Schmitt, Anita [VerfasserIn]
• Verfasst von: Malcherek, Georg [VerfasserIn]
• Verfasst von: Hundemer, Michael [VerfasserIn]
• Verfasst von: Mani, Jiju [VerfasserIn]
• Verfasst von: Hose, Dirk [VerfasserIn]
• Verfasst von: Raab, Marc-Steffen [VerfasserIn]
• Verfasst von: Ho, Anthony Dick [VerfasserIn]
• Verfasst von: Goldschmidt, Hartmut [VerfasserIn]
• Verfasst von: Schmitt, Michael [VerfasserIn]
• Titel: T cell-based targeted immunotherapies for patients with multiple myeloma
• Verf.angabe: Lei Wang, Nan Jin, Anita Schmitt, Jochen Greiner, Georg Malcherek, Michael Hundemer, Jiju Mani, Dirk Hose, Marc S. Raab, Anthony D. Ho, Bao-an Chen, Hartmut Goldschmidt and Michael Schmitt
• Jahr: 2015
• Umfang: 18 S.
• Fussnoten: Online 8 September 2014 ; Gesehen am 11.07.2017
• Titel Quelle: Enthalten in: International journal of cancer
• Ort Quelle: Bognor Regis : Wiley-Liss, 1966
• Jahr Quelle: 2015
• Band/Heft Quelle: 136(2015), 8, Seite 1751-1768
• ISSN Quelle: 1097-0215
• DOI: doi:10.1002/ijc.29190
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: clinical trials
• Sach-SW: genetic engineering
• Sach-SW: immunotherapy
• Sach-SW: multiple myeloma
• Sach-SW: tumor antigens
• K10plus-PPN: 1560723807

Abstract

Despite high-dose chemotherapy followed by autologs stem-cell transplantation as well as novel therapeutic agents, multiple myeloma (MM) remains incurable. Following the general trend towards personalized therapy, targeted immunotherapy as a new approach in the therapy of MM has emerged. Better progression-free survival and overall survival after tandem autologs/allogeneic stem cell transplantation suggest a graft versus myeloma effect strongly supporting the usefulness of immunological therapies for MM patients. How to induce a powerful antimyeloma effect is the key issue in this field. Pivotal is the definition of appropriate tumor antigen targets and effective methods for expansion of T cells with clinical activity. Besides a comprehensive list of tumor antigens for T cell-based approaches, eight promising antigens, CS1, Dickkopf-1, HM1.24, Human telomerase reverse transcriptase, MAGE-A3, New York Esophageal-1, Receptor of hyaluronic acid mediated motility and Wilms' tumor gene 1, are described in detail to provide a background for potential clinical use. Results from both closed and on-going clinical trials are summarized in this review. On the basis of the preclinical and clinical data, we elaborate on three encouraging therapeutic options, vaccine-enhanced donor lymphocyte infusion, chimeric antigen receptors-transfected T cells as well as vaccines with multiple antigen peptides, to pave the way towards clinically significant immune responses against MM.